Abstract 30P
Background
Male breast cancer (MBC) is an uncommon malignancy with an estimated incidence of less than 1 % of all breast cancer cases. It is a disease of elderly arising in 6th to 7th decade. Patients usually present at an advanced stage with early skin and nodal involvement. Age, testicular disorders, liver cirrhosis, exogenous estrogens, BRCA -2 mutations are proposed etiological factors. There are four Population based cancer registries (PBCR) in Punjab, India. Amongst them two are predominantly urban (Chandigarh and SAS Nagar) and two are predominantly rural (Sangrur and Mansa). Sangrur PBCR is based at Homi Bhabha Cancer Hospital (under aegis of Tata Memorial Center, Mumbai). The aim of this study is to look into the incidence and clinico-pathological characteristics of M.B.C at our institute, mainly catering to a rural population.
Methods
A total of 1735 breast cancer cases registered over a period of 4 ½ years from January 2015 to July 2019 were screened. Online records were accessed.
Results
A total of 34 M.B.C cases were identified amounting for 1.9% of all breast cancer cases. All patients were from Punjab except one. 44.1% were from district Sangrur. If we look at district wise ratio of MBC to total breast cancer cases then Barnala (2.3) is followed by Mansa (2.1) followed by Sangrur (2.09). Mean Age was 62.5 years. Mean BMI (N=20) was 23.9. Family history was not significant in any case. Tumor was localized to right in 64.7 % cases. Most of the tumors were central in location (70.6%). Main complaint was lump in 58.8%. 16 patients were metastatic,10 were LABC, 8 were early stage. All were infiltrating ductal carcinoma. 27 were ER +ve, 25 were PR +ve, 1 was her2neu positive, 1 was Triple negative. 7 patients were Luminal A, 8 were Luminal B, 1 was Basal, 6 were unknown due to missing information,12 were Luminal A/B. 13 patients were treated radically, 9 were palliative & 12 patients defaulted. 4 patients with oligo-metastatis treated radically were alive at last presentation. 2 patients underwent palliative mastectomy.
Conclusions
Our ratio of M.B.C to breast cancer cases is 1.9 % which is higher than average of 1%. Study period in our series is only 4 1/2 years unlike others, usually more than a decade, with equivalent number of cases. Unlike other studies our burden of metastatic disease was more.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sachin Khandelwal.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session